Xenon Pharmaceuticals(XENE)

Focus: Xenon Pharmaceuticals is a public biotech company focused on small-molecule therapeutics for rare genetic diseases, particularly in neurology and seizure disorders. The company is pre-commercial with a lean operational footprint and a concentrated pipeline in neurology.

Rare Diseases Neurology

Profile data last refreshed 4h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

23+5 this month

Growing — net +5 jobs in 30d

12 jobs added vs 7 removed. Steady team buildout.

Should You Work at Xenon Pharmaceuticals?

AI assessment

Xenon is a high-risk, high-reward opportunity for professionals seeking early-stage exposure to late-phase pipeline catalysts in neurology, but clinical trial outcomes over the next 12-24 months will determine long-term career stability.

Why Work Here

Strong Phase 3 pipeline with 11 active Phase 3 programs (XEN496, XEN1101, Azetukalner) addressing high-unmet-need indications in epilepsy, seizure disorders, and depression

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Late-stage

11 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$0K

Pipeline & Clinical Trials

XEN901

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT03467100Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901

Phase 1

Help build intelligence for Xenon Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Active hiring momentum (18 open roles) concentrated in Clinical Development (7 roles) and Commercial (5 roles), signaling imminent commercialization phase

Focused therapeutic strategy in rare/genetic neurological diseases reduces competitive pressure versus mega-pharma and allows for specialized expertise building

Watch Out For

Significant cash burn: $182M net loss in FY2025 on only $9M revenue (FY2024), with just $143M cash on hand—runway sustainability depends entirely on Phase 3 clinical success
Pre-commercial stage with zero marketed products limits stability; single failed Phase 3 trial could materially impact company viability and job security

Generated by Claude from Xenon Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

14C-XEN1101

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT04952467Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101

Phase 1

XPF-001

Healthy Human Volunteers

PHASE_1

Clinical Trials (1)

NCT00813670Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers

Phase 1

XPF-008

Healthy Male Volunteers

PHASE_1

Clinical Trials (1)

NCT03468725Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101

Phase 1

XPF-008

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT03340220Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.

Phase 1

XPF-005

Acne Vulgaris

PHASE_1_2

Clinical Trials (1)

NCT02656043A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel

Phase 1/2

XPF-002

Primary Erythromelalgia

PHASE_1_2

Clinical Trials (1)

NCT01486446Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

Phase 1/2

XPF-001

Primary Erythromelalgia

PHASE_1_2

Clinical Trials (1)

NCT01090622Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

Phase 1/2

XPF-002

Postherpetic Neuralgia

PHASE_2

Clinical Trials (1)

NCT01195636A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

Phase 2

XEN1101

Focal Epilepsy

PHASE_2

Clinical Trials (1)

NCT03796962A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

Phase 2

XEN1101 10 mg

Major Depressive Disorder

PHASE_2

Clinical Trials (1)

NCT05376150A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

Phase 2

XPF-001

Dental Pain

PHASE_2

Clinical Trials (1)

NCT00954356Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

Phase 2

XEN1101

Focal Onset Seizures

PHASE_3

Clinical Trials (1)

NCT05614063A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

Phase 3

XEN496

Epilepsy

PHASE_3

Clinical Trials (1)

NCT04912856An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

Phase 3

Azetukalner

Bipolar Depression

PHASE_3

Clinical Trials (1)

NCT07217860An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

Phase 3

XEN1101

Focal Epilepsy

PHASE_3

Clinical Trials (1)

NCT05718817An Open-label Study of XEN1101 in Epilepsy

Phase 3

XEN1101

Primary Generalized Tonic-Clonic Seizures

PHASE_3

Clinical Trials (1)

NCT05667142A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Phase 3

XEN1101

Focal Onset Seizures

PHASE_3

Clinical Trials (1)

NCT05716100A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

Phase 3

Azetukalner

Major Depressive Disorder

PHASE_3

Clinical Trials (1)

NCT06775379A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

Phase 3

Azetukalner

Major Depressive Disorder

PHASE_3

Clinical Trials (1)

NCT07076407A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

Phase 3

Azetukalner

Bipolar Disorder

PHASE_3

Clinical Trials (1)

NCT07172516A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Phase 3

Azetukalner

Major Depressive Disorder

PHASE_3

Clinical Trials (1)

NCT06922110An Open-Label Study of Azetukalner in Major Depressive Disorder

Phase 3

XEN496

Epilepsy

PHASE_3

Clinical Trials (1)

NCT04639310XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

Phase 3

Interview Prep Quick Facts

Portfolio: 23 clinical trials

Top TAs: Neurology

SEC Filings: 2 available

Open Roles: 23 active jobs

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

9 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$0100%

R&D Spend

$168M58%

Net Income

-$182M

Cash

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Xenon Pharmaceuticals(XENE)

Should You Work at Xenon Pharmaceuticals?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (23)

Director/Senior Director, CMC, Drug Substance

Director, Human Resources

Data Scientist

Senior Manager, Trial Operations

Senior Manager, Trial Operations

Director, CMC, Drug Product

Director/Senior Director, Supply Chain

Director, Pricing & Contracting

Director, CMC, Drug Product

Senior Manager, Regulatory Affairs, Operations

Senior Manager/Associate Director, Commercial & Medical Information Systems

Director/Senior Director, Forecast & Research

Senior Director, US Patient Marketing

Senior Manager/Associate Director, Access Marketing

Senior/Principal Statistical Programmer

Senior Director, Field Strategy & Enablement

Senior Medical Science Liaison (NYC Tri-State)

Director, Distribution & Services

Senior Director, Supply Chain, Logistics

Associate Director, Scientific Communications

Medical Director/Senior Medical Director, Drug Safety and Pharmacovigilance, Medical Safety

Associate Director/Director, Quality Assurance, GCP

Senior Medical Director, Clinical Development Psychiatry (BPD)

Financials (FY2025)

Hiring Trend